Clinical Trials Browser

Phase 1/2 × Recurrence × Idarubicin × Clear all

NCT01289457 2020-02-24

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Phase 1/2 Completed

282 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute